Background: Ketamine rapidly improves depressive symptoms in patients with treatment-resistant major depressive disorder (MDD) who do not respond to multiple standard antidepressants. However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT). Conclusion: Ketamine appears to improve depressive symptoms in patients with MDD who had previously not responded to ECT. These preliminary results encourage further investigation with a larger sample size to determine effectiveness compared to other treatment-resistant patients with MDD.
Introduction
Major depressive disorder (MDD) is a common, chronic, severe, and often life threatening illness, with a lifetime prevalence estimated at 16.2% (Kessler et al., 2003) . Indeed, the World Health Organization's Global Burden of Disease Study identified MDD as the leading cause of disability in the Western World for those aged 15-44 (The World Health Organization, 2000) . Currently available therapeutic approaches for MDD are not effective for a substantial number of patients; furthermore, a considerable therapeutic lag before clinical improvement is seen in those patients who do respond (Rush et al., 2006) . Data from inpatient populations with MDD that used algorithm-guided treatments (including electroconvulsive therapy (ECT)) demonstrated remission rates between 50 and 54%; in addition, these algorithms included the use of medications at higher than FDA-recommended dosages, and had higher dropout rates than treatment-as-usual (Bauer et al., 2009; Birkenhager et al., 2006) .
ECT has long been considered the gold standard therapeutic approach for treatment-resistant MDD (Fink, 1990; UK ECT Review Group, 2003) , and has also been described as the most effective treatment for MDD due to its having the largest effect size of all available treatments (Fava, 2003) . Traditionally, one of the main indications for receiving ECT has been non-response to multiple antidepressant trials (Thase and Rush, 1997) . One meta-analysis found that the probability of responding to ECT was almost four times greater than the probability of responding to antidepressants (Pagnin et al., 2004) . In addition, ECT has also been associated with more rapid onset of antidepressant effects than standard antidepressants (Fava, 2003) . For instance, the Consortium for Research in ECT (CORE) noted that more than half of patients treated with ECT showed improvement during the first week, and 65% achieved remission after 10 sessions (Husain et al., 2004) . Another group reported that remission rates with ECT were as high as 70-90% (UK ECT Review Group, 2003) . Despite these favorable data, ECT is often reserved as the last choice for treating MDD (Pagnin et al., 2004 
